

1 **A method for the generation of large numbers of dendritic cells from CD34+ hematopoietic**  
2 **stem cells from cord blood**

3

4 Nicole Bedke, PhD<sup>1</sup>, Emily J. Swindle, PhD<sup>1</sup>, Camelia Molnar, MSc,<sup>1</sup> Patrick Holt,  
5 PhD<sup>2</sup>, Deborah Strickland, PhD<sup>2</sup>, Graham C. Roberts, DM<sup>1</sup>, Ruth Morris RSCN<sup>1</sup>, Stephen T.  
6 Holgate, DSc, MD,<sup>1</sup> Donna E. Davies, PhD<sup>1</sup>, Cornelia Blume, PhD<sup>1</sup>

7

8 <sup>1</sup>: Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of  
9 Southampton, Southampton, UK

10 <sup>2</sup>: Telethon Institute for Child Health Research, Centre for Child Health Research, University of  
11 Western Australia, Perth, Australia

12

13 *Corresponding Author:*

14 Dr. Cornelia Blume

15 Clinical and Experimental Sciences

16 Faculty of Medicine

17 University of Southampton

18 Southampton, United Kingdom

19 Tel: +44 2381 203308

20 Email: [C.Blume@soton.ac.uk](mailto:C.Blume@soton.ac.uk)

21

22 **Abstract (300 words max)**

23 Dendritic cells (DCs) play a central role in regulating innate and adaptive immune responses. It  
24 is well accepted that their regulatory functions change over the life course. In order to study DCs  
25 function during early life it is important to characterize the function of neonatal DCs. However,  
26 the availability of neonatal DCs is limited due to ethical reasons or relative small samples of cord  
27 blood making it difficult to perform large-scale experiments. Our aim was to establish a robust  
28 protocol for the generation of neonatal DCs from cord blood derived CD34+ hematopoietic stem  
29 cells. For the expansion of DC precursor cells we used a cytokine cocktail containing Flt-3L,  
30 SCF, TPO, IL-3 and IL-6. The presence of IL-3 and IL-6 in the first 2 weeks of expansion  
31 culture was essential for the proliferation of DC precursor cells expressing CD14. After 4 weeks  
32 in culture, CD14+ precursor cells were selected and functional DCs were generated in the  
33 presence of GM-CSF and IL-4. Neonatal DCs were then stimulated with Poly(I:C) and LPS to  
34 mimic viral or bacterial infections, respectively. Poly(I:C) induced a higher expression of the  
35 maturation markers CD80, CD86 and CD40 compared to LPS. In line with literature data using  
36 cord blood DCs, our Poly(I:C) matured neonatal DCs cells showed a higher release of IL-12p70  
37 compared to LPS matured neonatal DCs. Additionally, we demonstrated a higher release of IFN-  
38  $\gamma$ , TNF- $\alpha$ , IL-1 $\beta$  and IL-6, but lower release of IL-10 in Poly(I:C) matured compared to LPS  
39 matured neonatal DCs derived from cord blood CD34+ hematopoietic stem cells. In summary,  
40 we established a robust protocol for the generation of large numbers of functional neonatal DCs.  
41 In line with previous studies, we showed that neonatal DCs generated from CD34+ cord blood  
42 progenitors have a higher inflammatory potential when exposed to viral than bacterial related  
43 stimuli.

44

45

46 **Keywords:** neonatal dendritic cells, CD34+ hematopoietic stem cells, cord blood, maturation,  
47 Poly(I:C), lipopolysaccharide

48

49

50 **Highlights:** (3-5 bullet points, each max. 85 characters incl. spaces)

- 51
- A robust protocol for the generation of high numbers of neonatal dendritic cells
  - IL-3 and IL-6 are crucial for the proliferation of cord blood CD34<sup>+</sup> progenitors
- 52

- 53 • Neonatal DCs have a higher inflammatory potential when exposed to viral stimuli
- 54 • LPS induces higher release of IL-10 in neonatal DCs compared to Poly(I:C)
- 55

56

## 1. Introduction

57 Dendritic cells (DCs) act as sentinels of the immune system and therefore play a key role  
58 in triggering and priming immune responses to environmental agents. Through expression of  
59 receptors they sense infections and are able to link innate and adaptive immune response at  
60 epithelial interfaces (Hammad and Lambrecht, 2011). Through mediators including TSLP, OX40  
61 ligand, GM-CSF, CCL20 and others released by the infected or damaged tissue, e.g. epithelial  
62 surfaces, DCs are recruited to the site of infection (Gill, 2012). In response, DCs are activated,  
63 migrate to draining lymph nodes and upregulate MHCII, co-activation receptors including CD80  
64 and CD86 and secrete cytokines which can then instruct naive T-cells (Th0) to differentiate into  
65 Th1, Th2-cells, Treg or Th17 cells.

66 It is now well accepted that the characteristics of DCs change and mature during life  
67 (Willems et al., 2009; Basha et al., 2014; Agrawal et al., 2017). In order to understand the role of  
68 DCs over the life course, it becomes important to consider the source of DCs when studying their  
69 responses to environmental agents. In particular, due to the limited availability of neonatal DCs,  
70 it is challenging to investigate the characteristics of DCs at early life in detail. Hematopoietic  
71 stem cells (HSCs) have increasingly become an important tool to generate large numbers of  
72 immune cells of specific lineages due to their plasticity in being able to differentiate into a  
73 desired cell type depending on the cytokines they are exposed to. Specifically, methods to  
74 generate large numbers of DCs from CD34<sup>+</sup> HSCs from cord blood (CB) using different  
75 cytokine cocktails have been developed, mainly for cancer immunotherapy (Balan et al., 2009;  
76 Harada et al., 2011; Plantinga et al., 2019). Our aim was to establish a robust protocol for  
77 obtaining large numbers of DCs from cord blood derived CD34<sup>+</sup> HSCs. To assess functionality,  
78 we compared the responses of CB-derived neonatal DCs following exposure to the TLR3 ligand  
79 polyinosinic:polycytidylic acid (Poly(I:C)), an analogue of viral double-stranded RNA, and to  
80 the TLR4 ligand lipopolysaccharide (LPS), a component of the outer membrane of Gram-  
81 negative bacteria.

82

## 83 2. Materials and Methods

84 *2.1. Isolation of cord blood mononuclear cells (CBMCs)*

85           CB samples were obtained following informed consent from mothers undergoing elective  
86 C-section (ethics code 07/Q1704/21 and 10/H0502/11) at the Princess Anne Maternity Hospital,  
87 Southampton and were processed within 30 minutes of collecting. CBMCs were isolated by  
88 means of Ficoll-Hypaque (GE Healthcare Life Sciences, Buckinghamshire, UK) gradient  
89 centrifugation and cryopreserved in 7.5 % DMSO / 50 % fetal bovine serum (FBS) until further  
90 use. CBMCs were thawed rapidly in a 37°C water bath and media added. The cell suspension  
91 was centrifuged and incubated in the presence of DNase I solution (Stemcell Technologies,  
92 Grenoble, France) for 15 mins at room temperature. Cells were then counted and further used for  
93 magnetic isolation of CD34<sup>+</sup> progenitor cells.

#### 94           2.2. *Isolation and expansion of CD34<sup>+</sup> progenitor cells*

95           CD34<sup>+</sup> progenitor cells were obtained by magnetic isolation using the EasySep™ Human  
96 CD34 Positive selection kit (Stemcell Technologies, Grenoble, France) prior to plating in 24-  
97 well or 6-well plates at a cell density of 5 x 10<sup>4</sup> cells per ml. Progenitor cells were cultured in  
98 IMDM (Life Technologies, Paisley, UK) containing 10% (v/v) heat-inactivated HI-FBS, 5  
99 units/ml Penicillin G Sodium and 50 µg/ml Streptomycin sulphate, 0.1 mM β-mercaptoethanol  
100 (IMDM complete) with either 25 ng/ml Fms-related tyrosine kinase 3-Ligand (Flt-3L), 10 ng/ml  
101 Stem cell factor (SCF), 10 ng/ml Interleukin-3 (IL-3), 10 ng/ml IL-6 (IL-6) collectively called  
102 FS36 or 25 ng/ml Flt-3L, 10 ng/ml SCF, 10 ng/ml Thrombopoietin (TPO), collectively called  
103 FTS and incubated at 37°C, 5% CO<sub>2</sub> for a total of 28 days. Cells were cultured either for 1) 2  
104 weeks in FS36, followed by 2 weeks in FTS; 2) 3 weeks in FS36, followed by 1 week in FTS; or  
105 3) 4 weeks in FTS. After 7 days, cells were collected, centrifuged at 300 x g, 10 mins, RT,  
106 counted and re-seeded at 5 x 10<sup>4</sup> cells per ml. At days 14 and 21, the cell densities were  
107 increased to 2 x 10<sup>5</sup> cells per ml. At day 28, cells were seeded into a 6-well plate at 1 x 10<sup>6</sup> cells  
108 per ml without FBS and incubated for 10 mins. Non-adherent cells were removed by washing  
109 twice with IMDM. Fresh media (IMDM complete) containing 20 ng/ml IL-4 and 50 ng/ml GM-  
110 CSF was then added to the adherent cells and cultured for another 5-6 days. Cells were fed every  
111 second day by semi-depletion with fresh IMDM complete containing GM-CSF and IL-4. All  
112 cytokines and growth factors were purchased from Peprotech (London, UK). For analysis of cell  
113 surface markers, cells were incubated and stained with fluorescent-conjugated antibodies to the  
114 cell surface markers CD1a, CD14, CD33 and CD34, (BD Biosciences, Oxford, UK) according to  
115 manufacturer's instructions. Whole cell populations were gated and analyzed by flow cytometry

116 using a FACS Calibur. A Fixation and Dead Cell Discrimination Kit (Miltenyi Biotec, Surrey,  
117 UK, #130-091-163) was used according to the manufacturer's instructions to gate out  
118 populations of dead cells during analysis. The gating strategy is shown in Supplementary Figure  
119 1.

### 120 *2.3. Stimulation and characterization of CBDCs*

121 After GM-CSF and IL-4 treatments, cells were plated at a density of  $5 \times 10^5$  cells per ml  
122 in a 12-well plate. High-molecular weight polyinosinic:polycytidylic acid (PolyI:C, 1.5–  
123 8kb)(Invivogen, Toulouse, France) or lipopolysaccharide (LPS) (Sigma, Dorset, UK) were added  
124 to cells at a concentration 10  $\mu\text{g/ml}$  or 100-500 ng/ml respectively. Cells were incubated for 24  
125 hrs at 37°C, 5% CO<sub>2</sub>. For analysis of cell surface markers, cells were incubated and stained with  
126 fluorescent-conjugated antibodies to the cell surface markers CD1a, CD14, CD33, CD34, HLA-  
127 DR, CD40, CD80, CD86 (BD Biosciences, Oxford, UK) according to manufacturer's  
128 instructions. Whole cell populations were gated and analyzed by flow cytometry using a FACS  
129 Calibur. A Fixation and Dead Cell Discrimination Kit (MiltenyiBiotec) was used to gate out  
130 population of dead cells during analysis.

### 131 *2.4. Cytokine assay*

132 Cell supernatants were analyzed for secretion of human IFN- $\gamma$ , IL-1 $\beta$ , IL-6, IL-10, IL-  
133 12p70 and TNF- $\alpha$  using a multi-array cytokines assay according to manufacturer's instructions  
134 (Meso Scale Discovery, Rockville, USA).

### 135 *2.5. Statistical analysis*

136 Statistical evaluation was performed using the software SigmaPlot 12.5. If not stated  
137 otherwise, related samples were analyzed for statistical significance using the Shapiro-Wilk test  
138 for normality followed by a paired Student's t-test or Wilcoxon Signed Rank test. Differences  
139 were regarded as significant when  $P \leq 0.05$ . For multiple comparisons, ANOVA followed by  
140 Tukey test or the non-parametric Friedman followed by Dunn's was performed.

141

## 142 **3. Results**

143            *3.1. Establishment of expansion cell cultures from cord blood CD34<sup>+</sup> hematopoietic stem*  
144            *cells*

145            Our aim was to establish a robust method to expand precursors of DCs from CB CD34<sup>+</sup>  
146 HSCs for the generation of DCs that can be used for analyzing neonatal immune responses.  
147 Work published by Balan *et al.*, (2009) used IMDM medium supplemented with a cytokine  
148 cocktail containing 25ng/ml Flt3-L, 10ng/ml TPO and 20ng/ml SCF and 5% heat-inactivated  
149 autologous cord blood plasma. However, using these conditions in our experiments, the CB stem  
150 cells failed to survive beyond day 7. Therefore, we altered the culture conditions based on data  
151 from the literature (Bontkes *et al.*, 2002). After purification of CB CD34<sup>+</sup> cells by magnetic  
152 separation CD34<sup>+</sup>, cells were cultured for a total of 4 weeks in either medium containing Flt3-L,  
153 SCF, IL-3 and IL-6 (FS36) for 2 weeks followed by 2 weeks days in Flt3-L, TPO and SCF (FTS)  
154 or were cultured for 3 weeks in FS36 medium followed by 1 week in FTS. As a comparison,  
155 cells were also cultured for 4 weeks in FTS alone. We obtained the highest number of CD34<sup>+</sup>  
156 derived progenitor cells when cultures were grown in the presence of IL-3 and IL-6 (Figure 1A),  
157 which is in line with previous observations (Bontkes *et al.*, 2002). The ability of CD34<sup>+</sup> HSCs to  
158 proliferate was highest within the first 2 weeks of culture after which cell numbers plateaued or  
159 decreased slightly (Figure 1A). This correlated with a decreased expression of the surface marker  
160 CD34 indicating that cells had lost their pluripotency (Supplementary Fig. 2S). Cells cultured for  
161 4 weeks in FTS showed very low proliferation demonstrating a key requirement for IL-3 and IL-  
162 6 for growth. After 4 weeks in culture the progenitor cells were further characterized by flow  
163 cytometry and both culture conditions showed comparable expression of cell-surface markers.  
164 The majority of cells were positive for the myeloid lineage marker CD33 (88 – 94%). Between  
165 25 – 30% were positive for the monocyte-specific marker CD14 (25 - 30%), and a low  
166 percentage of cells were positive for the DC specific marker CD1a (2.5 – 3.5%) and the  
167 hematopoietic stem cell marker CD34 (4.7 – 8.3%) (Figure 1B and C).

168  
169            *3.2. Generation of dendritic cells from expanded progenitor cells derived from cord blood*  
170            *CD34<sup>+</sup> hematopoietic stem cells.*

171            After 28 days of expansion culture using either 2W FS36 + 2W FTS or 3W FS36 + 1W  
172 FTS, DC were generated from the progenitor cells following culture for 5-6 days in the presence

173 of GM-CSF and IL-4. Use of 2W FS36 + 2W FTS or 3W FS36 + 1W FTS expansion culture  
174 resulted in a similar number of DCs (Figure 2A). After culture for 5-6 days in GM-CSF and IL-4  
175 neonatal DCs derived from either protocol expressed high levels of CD1a, a marker of DCs,  
176 HLA-DR and CD33, a marker of myeloid lineage, whereas expression of CD14, a monocyte  
177 specific marker CD14, was negligible (2W FS36 + 2W FTS:  $1.42 \pm 0.14$  % positive cells, MFI  
178  $3.0 \pm 0.69$ ; 3W FS36 + 1W FTS:  $2.42 \pm 0.08$  % positive cells, MFI of  $3.65 \pm 0.68$  (mean  $\pm$   
179 SEM)) (Figure 2B-D). Over 60% of the cells were CD11c<sup>+</sup>HLA-DR<sup>+</sup> (Supplementary Figure 3S).  
180 This marker profile identifies the cells as DCs. There was no difference in the ability of the DC  
181 progenitor cells obtained from the two different expansion culture conditions to differentiate into  
182 DCs. These data demonstrate that high numbers of neonatal DCs can be generated from CD34<sup>+</sup>  
183 HSC from cord blood.

184

### 185 *3.3. Maturation of DCs*

186 Next we investigated whether the CB-derived neonatal DCs generated from precursors  
187 expanded using the 2 different culture conditions described above showed any differences in  
188 their ability to mature. Following exposure to the TLR3 ligand Poly(I:C) the expression levels of  
189 CD40, CD80 and B7H1 were significantly increased compared to the unexposed control in  
190 CBDCs generated from 2W FS36 +2W FTS expansion cultures and the expression levels of  
191 HLA-DR, CD80, CD86 and B7H1 were significantly increased compared to the unexposed  
192 control in CBDCs generated from 3W FS36 +1W FTS expansion cultures (Figure 3). However,  
193 the fold induction of these surface markers in Poly(I:C) exposed CBDCs compared to the  
194 unexposed control was comparable between the two different expansion methods used for the  
195 DCs precursor cells. After maturation, DCs release a variety of cytokines that are able to  
196 modulate T cell function. Therefore, we compared the cytokine profile of mature CBDCs  
197 generated from precursors that have been expanded using the two different culture conditions. As  
198 shown in Figure 4, mature CBDCs showed an increased release of IFN- $\gamma$ , IL-1 $\beta$ , IL-6, IL-10, and  
199 TNF- $\alpha$  but only IFN- $\gamma$  reached statistical significance. Release of IL-12p70 was unchanged.  
200 Furthermore, there was no difference between the culture conditions in the levels of cytokines  
201 generated. In summary, we did not observe any difference in the maturation of CBDCs derived  
202 from precursors that have been expanded using the two different expansion culture conditions.



203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221

### 3.4. TLR-dependent maturation of CBDCs

In order to assess the potential of CBDCs to mature in response to different TLR stimuli we analyzed their response to the TLR4 agonist LPS and to the TLR3 agonist Poly(I:C). For this set of experiments, we used neonatal DCs that had been generated from 2W FS36 + 2W FTS expansion cultures since expansion was slightly higher using this culture condition and the ability of neonatal DCs to mature was not affected by the expansion culture condition. As shown in Figure 5, Poly(I:C) at 10µg/ml induced a significantly higher expression of the maturation markers CD80, CD86, and CD40 compared to LPS used at 100µg/ml and 500µg/ml. Expression of HLA-DR showed no significant change. Since 100µg/ml LPS induced a slightly higher CD80 and CD86 expression than 500µg/ml LPS, we used this concentration of LPS to analyze the cytokine release further. Additionally, we chose 10µg/ml Poly(I:C) to mimic virally induced maturation as this concentration showed a significant effect on maturation marker expression by neonatal DCs compared to LPS, which mimics bacterial induced maturation. Interestingly, release of IL-10 was only significantly increased by LPS, whereas release of IL-6, TNF-α and IL-1β were only significantly increased by Poly(I:C) compared to the control (Figure 6). These results suggest that neonatal DCs show a higher inflammatory potential when maturation is induced by virus-related compared to bacteria-related components.

## 4. Discussion

DCs play an important role in bridging the innate and adaptive immune response to infection. It is known that immune responses change over the life course (Simon et al., 2015) and DCs are thought to be centrally involved in the priming process. However, the availability of neonatal human DCs for functional *in vitro* studies is limited resulting in an unmet need for a source of large numbers of neonatal DCs that can be used in detailed mechanistic studies. Therefore, our aim was to establish a robust protocol for the generation of high numbers of DCs from CB-derived HSCs that have a more ‘naïve’ phenotype and can be used to investigate the characteristics of DCs in the context of early life. Previous studies have used CD34<sup>+</sup> HSCs cultured in a cocktail of growth factors to expand precursors and drive their differentiation into DCs. While Chang et al. (2012) expanded cord blood derived CD34<sup>+</sup> HSCs by using SCF only for expansion cultures, Harada et al. (2011) used a combination of GM-CSF and SCF. Arrighi et

234 al. (1999) and Balan et al. (2009) expanded CD34<sup>+</sup> HSC from cord blood using a cocktail of Flt-  
235 3L, TPO and SCF. Using this cocktail for expansion, we only observed a moderate expansion of  
236 DC precursor cells. Interestingly, when using heat-inactivated autologous serum instead of FCS  
237 as described by Balan et al. (2009), cells failed to survive for more than one week in culture.  
238 Therefore, we aimed to optimize the expansion culture conditions in order to increase the  
239 proliferation rate of CD34<sup>+</sup> HSC from cord blood that would result in a high number of  
240 precursor cells that can be differentiated into functional DCs. We adapted an expansion protocol  
241 that was previously used for CD34<sup>+</sup> HSC from adult peripheral blood, where CD34<sup>+</sup> HSC using  
242 Flt3L, TPO, SCF, IL-3 and IL-6 followed by treatment with GM-CSF and IL-4 to generate DCs  
243 (Bontkes et al., 2002). As previously reported, we observed the highest increase in precursor  
244 cells in the presence of IL-3 and IL-6, which made a large-scale experimental setup more  
245 feasible. Ultimately, we were able to differentiate myeloid DCs that were  
246 CD1a<sup>+</sup>CD11c<sup>+</sup>CD40<sup>+</sup>HLA-DR<sup>+</sup> and CD14<sup>-</sup>CD123<sup>-</sup>, surface markers that are characteristic of  
247 human myeloid DCs (Baharom et al., 2017). Although it has been reported that DCs with high  
248 expression of CD11c can be obtained using only GM-CSF and SCF for expansion culture, these  
249 cells also expressed high levels of the monocyte marker CD14 (Harada et al., 2011). As the  
250 authors did not analyze expression of CD1a or CD123 it is difficult to compare the purity or  
251 functionality of the cells. Furthermore, it has been shown that CD34<sup>+</sup> CD117<sup>+</sup> cord blood cells  
252 are multipotent and able to develop into monocytes, granulocytes, B cells, pDCs, CD1c<sup>+</sup> and  
253 CD141<sup>+</sup> cDCs when co-cultured with stromal cells and Flt-3L, SCF and GM-CSF (Breton et al.,  
254 2015). This underlines the importance of the conditions used for expansion culture and  
255 differentiation which can determine the characteristics of the resulting cell populations. Further  
256 work will be required to fully characterize the surface marker expression for a in depth  
257 comparison of DC subtypes generated using our protocol. Previously, concerns have been raised  
258 about the prolonged presence of IL-3 and IL-6 in the expansion cultures leading to decreased  
259 levels of IL-12p70 and increased levels of IL-10 (Bontkes et al., 2002; Ebner et al., 2002).  
260 However, we did not observe any significant differences in the secretion of either cytokine from  
261 mature CBDCs generated from expansion cultures using IL-3 and IL-6 for the first two weeks or  
262 the first 3 weeks of expansion culture. A shorter GMP protocol, which has applicability in  
263 cancer immunotherapy, consisting of one week expansion culture with Flt-3L, SCF, IL-3 and IL-  
264 6 followed by one week differentiation into DCs using Flt-3L, SCF, GM-CSF and IL-4 has been

265 used by Plantinga et al. (2019) to expand CD34<sup>+</sup> stem cells into a population consisting of about  
266 34% CD11c<sup>+</sup>HLA-DR<sup>+</sup> DCs. In contrast, our method resulted in over 60% CD11c<sup>+</sup>HLA-DR<sup>+</sup>  
267 DCs. Additionally, Plantinga et al. demonstrated that CB-derived DCs originate exclusively from  
268 CD115<sup>+</sup> progenitor cells and resemble cDC2. In summary, we established a protocol that allows  
269 the generation of high numbers of neonatal DCs from CB-derived HSCs that can be used to  
270 analyze the DC immune response in an early life setting.

271 In our study, we analyzed the ability of CBDCs to respond to different stimuli. High  
272 molecular weight Poly(I:C), which is an analogue of double-stranded RNA that is produced  
273 during the replication cycle of certain viruses and has been shown to activate TLR3, RIG-  
274 I/MDA5 and PKR, caused a more Th1 biased cytokine profile with high IL-12, IFN- $\gamma$ , TNF- $\alpha$ ,  
275 IL-6 and IL-1 $\beta$  release. Using LPS to induce maturation, a bacterial membrane component of  
276 Gram-negative bacteria, we observed a significantly induced release of IL-10. These findings  
277 are consistent with previous studies using CB-monocyte derived DCs which showed that  
278 Poly(I:C) induced maturation resulted in higher IL-12p70 release compared to LPS (Goriely et  
279 al., 2001) and indicate that the immune responses specific for neonatal DCs are sustained in our  
280 model system.

281 Our observation of significantly increased IL-6 release from neonatal DCs during  
282 Poly(I:C) induced maturation, which mimics a viral infection, might have important modulatory  
283 functions during the polarization of naive T cells in early life. It has been shown that exogenous  
284 IL-6 in addition to TGF $\beta$  is an important factor during Th17 polarization (Swain et al., 2012;  
285 Martinez-Sanchez et al., 2018). While the role of Th17 cells in viral infections is not fully  
286 understood, there is evidence that Th17 cells can support neutrophil recruitment via release of  
287 IL-17 (Ye et al., 2001; Mukherjee et al., 2011). Additionally, Th17 cells are thought to play an  
288 important role in the anti-microbial host defense at mucosal surfaces (Rathore and Wang, 2016).  
289 In order to demonstrate the direct T cell stimulating ability of these DCs further experiments  
290 using DC-T cell co-cultures need to be performed. Through access to *in vitro* generated neonatal  
291 DCs, the mechanisms of innate and adaptive immune responses to viral and bacterial infections  
292 early in life can now be investigated in detail. This is of importance as this time in early life,  
293 described as the neonatal window of opportunity, is linked to the susceptibility for many immune  
294 disorders in later life (Torow and Hornef, 2017). In particular, this has the potential to identify

295 the mechanistic link between early life infections and the risk of developing chronic diseases  
296 later in life. Furthermore, there is evidence that innate immune responses of neonates are  
297 influenced by maternal factors in utero. For example, Hrdy et al. (2014) showed a higher IL-12  
298 gene expression in neonatal CB-DCs derived from allergic compared to non-allergic mothers.  
299 Interestingly, a reduced release of IL-6 was observed in CB-derived monocytes after stimulation  
300 with LPS in neonates with maternal allergy compared to non-allergic controls (Saghafian-  
301 Hedengren et al., 2008). However, further detailed mechanistic investigations are needed using  
302 neonatal DCs in order to establish a functional link infections early in life, IL-6 production, Th17  
303 cells function and the risk of developing chronic diseases later in life. In conclusion, we present  
304 here a robust protocol for the generation of high numbers of neonatal DCs that are derived from  
305 CD34+ HSCs from CB that can be used for mechanistic studies of early life immune responses.

306

307

308 **Acknowledgement:** This work was funded by the Medical Research Council UK (G0900453).

309 **Author Disclosure Statement:** The authors declare no competing interests.

310

## 311 **References**

- 312 Agrawal, A., Agrawal, S. and Gupta, S., 2017, Role of Dendritic Cells in Inflammation and Loss of  
313 Tolerance in the Elderly. *Front Immunol* 8, 896.
- 314 Arrighi, J.F., Hauser, C., Chapuis, B., Zubler, R.H. and Kindler, V., 1999, Long-term culture of human  
315 CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive  
316 amplification of a CD34(-)CD14(-) and a CD34(-)CD14(+) dendritic cell precursor. *Blood* 93, 2244-  
317 52.
- 318 Baharom, F., Rankin, G., Blomberg, A. and Smed-Sorensen, A., 2017, Human Lung Mononuclear  
319 Phagocytes in Health and Disease. *Front Immunol* 8, 499.
- 320 Balan, S., Kale, V.P. and Limaye, L.S., 2009, A simple two-step culture system for the large-scale  
321 generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells.  
322 *Transfusion* 49, 2109-21.
- 323 Basha, S., Surendran, N. and Pichichero, M., 2014, Immune responses in neonates. *Expert Rev Clin*  
324 *Immunol* 10, 1171-84.
- 325 Bontkes, H.J., De Gruijl, T.D., Schuurhuis, G.J., Scheper, R.J., Meijer, C.J. and Hooijberg, E., 2002,  
326 Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from  
327 healthy donor blood; growth factor combination determines proliferation rate and functional  
328 outcome. *Journal of leukocyte biology* 72, 321-9.

329 Breton, G., Lee, J., Zhou, Y.J., Schreiber, J.J., Keler, T., Puhr, S., Anandasabapathy, N., Schlesinger, S.,  
330 Caskey, M., Liu, K. and Nussenzweig, M.C., 2015, Circulating precursors of human CD1c+ and  
331 CD141+ dendritic cells. *The Journal of experimental medicine* 212, 401-13.

332 Chang, M.C., Lee, C.N., Chen, Y.L., Chiang, Y.C., Sun, W.Z., Hu, Y.H., Chen, C.A. and Cheng, W.F., 2012,  
333 Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses  
334 and anti-tumour effects. *Clin Sci (Lond)* 123, 347-60.

335 Ebner, S., Hofer, S., Nguyen, V.A., Furhapter, C., Herold, M., Fritsch, P., Heufler, C. and Romani, N., 2002,  
336 A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate  
337 into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine  
338 pattern. *J Immunol* 168, 6199-207.

339 Gill, M.A., 2012, The role of dendritic cells in asthma. *The Journal of allergy and clinical immunology* 129,  
340 889-901.

341 Goriely, S., Vincart, B., Stordeur, P., Vekemans, J., Willems, F., Goldman, M. and De Wit, D., 2001,  
342 Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. *J*  
343 *Immunol* 166, 2141-6.

344 Hammad, H. and Lambrecht, B.N., 2011, Dendritic cells and airway epithelial cells at the interface  
345 between innate and adaptive immune responses. *Allergy* 66, 579-87.

346 Harada, Y., Okada-Nakanishi, Y., Ueda, Y., Tsujitani, S., Saito, S., Fuji-Ogawa, T., Iida, A., Hasegawa, M.,  
347 Ichikawa, T. and Yonemitsu, Y., 2011, Cytokine-based high log-scale expansion of functional  
348 human dendritic cells from cord-blood CD34-positive cells. *Scientific reports* 1, 174.

349 Hrdy, J., Novotna, O., Kocourkova, I. and Prokesova, L., 2014, Gene expression of subunits of the IL-12  
350 family cytokines in moDCs derived in vitro from the cord blood of children of healthy and allergic  
351 mothers. *Folia Biol (Praha)* 60, 74-82.

352 Martinez-Sanchez, M.E., Huerta, L., Alvarez-Buylla, E.R. and Villarreal Lujan, C., 2018, Role of Cytokine  
353 Combinations on CD4+ T Cell Differentiation, Partial Polarization, and Plasticity: Continuous  
354 Network Modeling Approach. *Front Physiol* 9, 877.

355 Mukherjee, S., Lindell, D.M., Berlin, A.A., Morris, S.B., Shanley, T.P., Hershenson, M.B. and Lukacs, N.W.,  
356 2011, IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation  
357 of allergic disease. *Am J Pathol* 179, 248-58.

358 Plantinga, M., de Haar, C.G., Dunnebach, E., van den Beemt, D., Bloemenkamp, K.W.M., Mokry, M.,  
359 Boelens, J.J. and Nierkens, S., 2019, Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells  
360 Specifically Originate from CD115-Expressing Precursors. *Cancers (Basel)* 11.

361 Rathore, J.S. and Wang, Y., 2016, Protective role of Th17 cells in pulmonary infection. *Vaccine* 34, 1504-  
362 14.

363 Saghafian-Hedengren, S., Holmlund, U., Amoudruz, P., Nilsson, C. and Sverreremark-Ekstrom, E., 2008,  
364 Maternal allergy influences p38-mitogen-activated protein kinase activity upon microbial  
365 challenge in CD14+ monocytes from 2-year-old children. *Clin Exp Allergy* 38, 449-57.

366 Simon, A.K., Hollander, G.A. and McMichael, A., 2015, Evolution of the immune system in humans from  
367 infancy to old age. *Proc Biol Sci* 282, 20143085.

368 Swain, S.L., McKinstry, K.K. and Strutt, T.M., 2012, Expanding roles for CD4(+) T cells in immunity to  
369 viruses. *Nat Rev Immunol* 12, 136-48.

370 Torow, N. and Hornef, M.W., 2017, The Neonatal Window of Opportunity: Setting the Stage for Life-  
371 Long Host-Microbial Interaction and Immune Homeostasis. *J Immunol* 198, 557-563.

372 Willems, F., Vollstedt, S. and Suter, M., 2009, Phenotype and function of neonatal DC. *Eur J Immunol* 39,  
373 26-35.

374 Ye, P., Rodriguez, F.H., Kanaly, S., Stocking, K.L., Schurr, J., Schwarzenberger, P., Oliver, P., Huang, W.,  
375 Zhang, P., Zhang, J., Shellito, J.E., Bagby, G.J., Nelson, S., Charrier, K., Peschon, J.J. and Kolls, J.K.,  
376 2001, Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte

377 colony-stimulating factor expression, neutrophil recruitment, and host defense. The Journal of  
378 experimental medicine 194, 519-27.

379

380

## 381 **Figure Legends**

382

383 **Figure 1: Expansion of cord blood CD34+ progenitor cells using different cytokine**  
384 **cocktails.** A: proliferation of progenitor cells in the presence of different cytokine cocktails. B:  
385 Expression of surface markers after 28 days of culture. Mean±SEM. n=3-5 independent  
386 experiments each using different donors. C: Representative histogram overlays. (thin line:  
387 isotype control, grey infill: marker expression; 2W FS36+2W FTS: 2 weeks culture in Flt3-L,  
388 SCF, IL-3 and IL-6 followed by 2 weeks Flt3-L, TPO and SCF. 3W FS36+1W FTS: 3 weeks  
389 culture in Flt3-L, SCF, IL-3 and IL-6 followed by 1 weeks Flt3-L, TPO and SCF. 4W FTS: 4  
390 weeks Flt3-L, TPO and SCF.

391

392 **Figure 2: Expression of DC-specific surface markers of neonatal DCs generated from**  
393 **expanded CD34+ progenitor cells.** After 4 weeks of expansion culture using cytokine cocktails  
394 detailed in Materials and Methods section, neonatal DCs were generated using IL-4 and GM-  
395 CSF. A: The number of DCs generated using the 2 different expansion culture conditions is  
396 expressed per CD34+ haematopoietic stem cell (HSC). B and C: Expression of surface markers  
397 was analysed by flow cytometry. Mean fluorescence intensity (B) and % positive cells (C) of  
398 neonatal DCs generated from 2 different CD34+ cell expansion culture conditions. Mean±SEM.  
399 n=4 independent experiments using different donors. D: Representative histogram overlays of  
400 surface marker expression by neonatal DCs generated from 2W FS36 + 2W FTS expansion  
401 cultures. (thin line: isotype control, grey infill: marker expression)

402

403 **Figure 3: Expression of maturation markers by neonatal DCs.** After expansion of CD34+  
404 haematopoietic stem cells using 2 different cytokine cocktails and differentiation into DCs  
405 maturation was induced by incubation with Poly(I:C) for 24h. Expression of surface markers on  
406 immature and mature DCs was analysed by flow cytometry. A: Expression of maturation  
407 markers by neonatal DCs that have been generated from expansion cultures using 2 weeks Flt-3L,

408 SCF, IL-3 and IL-6 followed by 2 weeks in Flt-3L, TPO and SCF (2W FS36+2W FTS). B:  
409 Expression of maturation markers by neonatal DCs generated from expansion cultures using 3  
410 weeks Flt-3L, SCF, IL-3 and IL-6 followed by 1 weeks in Flt-3L, TPO and SCF (3W FS36+1W  
411 FTS). C: Fold induction of maturation markers by mature neonatal DCs normalised to the level  
412 of immature DCs generated from CD34+ expansion cultures using 2 different cytokine cocktails.  
413 Mean±SEM. n=4 independent experiments using different donors. \*:  $p \leq 0.05$

414

415 **Figure 4: Release of cytokines by neonatal DCs after maturation.** Neonatal DCs were  
416 generated from CD34+ progenitors using 2 different cytokine cocktails for expansion culture as  
417 described in the Method section. DCs were matured by incubation with 10µg/ml Poly(I:C) for  
418 24h and the release of mediators determined in cell-free supernatants by multiplex assay. A: IL-  
419 12p70; B: IL-10; C: IFN-γ; D: IL-6; E: TNF-α; F: IL-1β. Mean±SEM. n=4 independent  
420 experiments using different donors. \*:  $p \leq 0.05$

421

422 **Figure 5: Expression of maturation markers by neonatal DCs varies with different TLR**  
423 **activation.** Neonatal DCs were incubated for 24h with the TLR4 ligand LPS or the TLR3 ligand  
424 Poly(I:C) and the expression of surface markers analyzed by flow cytometry. A: CD80; B: CD86;  
425 C: CD40; D: HLA-DR. Results shown are means ± SEM, n=4 independent experiments using  
426 different donors. \*:  $p \leq 0.05$  (ANOVA followed by Tukey multiple comparisons test).

427

428 **Figure 6: Differential release of cytokines after maturation of neonatal DCs with TLR3 or**  
429 **TLR4 ligands.** After incubation with LPS (TLR4 ligand) or Poly(I:C) (TLR3 ligand) for 24h the  
430 release of mediators was analysed in the cell culture supernatants by multiplex assay. A: IL-  
431 12p70; B: IL-10; C: IFN-γ; D: IL-6; E: TNF-α; F: IL-1β. Results shown are means ± SEM, n=4  
432 independent experiments using different donors. \*:  $p \leq 0.05$  compared to control (Friedman test  
433 followed by Dunn's multiple comparisons test).